Our study demonstrated that HER2/CEP17 ratio was a significant predictor for both RCB 0/I and pCR and for PFS in patients with HER2-positive breast cancer treated with neoadjuvant chemo-immunotherapy using pertuzumab and trastuzumab. Here, ERBB2 is linked to breast carcinoma.